Leading science, pioneering therapies
CRM Publications

Stem cell mobilization and collection in patients with liver cirrhosis.

TitleStem cell mobilization and collection in patients with liver cirrhosis.
Publication TypeJournal Article
Year of Publication2008
AuthorsLorenzini S, Isidori A, Catani L, Gramenzi A, Talarico S, Bonifazi F, Giudice V, Conte R, Baccarani M, Bernardi M, Forbes SJ, Lemoli RM, Andreone P
JournalAliment Pharmacol Ther
Volume27
Issue10
Pagination932-9
Date Published2008 May
ISSN1365-2036
KeywordsAdult, Aged, Antigens, CD, Antigens, CD34, Dose-Response Relationship, Drug, Feasibility Studies, Female, Glycoproteins, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Humans, Leukapheresis, Liver Cirrhosis, Male, Middle Aged, Peptides, Peripheral Blood Stem Cell Transplantation, Treatment Outcome
Abstract

BACKGROUND: Bone marrow-derived stem cells (BMSC) and granulocyte colony-stimulating factor (G-CSF) have been proved to contribute to tissue regeneration after liver injury.

AIMS: To test the safety of G-CSF and define the exact dose capable of mobilizing BMSC in the majority of patients with liver cirrhosis; and to assess the feasibility of leukapheresis to collect BMSC from peripheral blood.

METHODS: In this study, we treated 18 patients affected by liver cirrhosis with increasing doses of G-CSF to mobilize CD34(+) and CD133(+) BMSC into the peripheral blood.

RESULTS: The dose-finding phase demonstrated that 15 microg/kg/day of G-CSF is the optimal dose to mobilize both CD34(+) and CD133(+) stem cells. Circulating BMSC were collected by a single step leukapheresis in three patients and the mean number of CD34(+) and CD133(+) cells cryopreserved was 1.3 +/- 0.7 and 1.2 +/- 0.5 x 10(6)/kg, respectively. No severe adverse events were observed during the drug administration and stem cell collection. Noteworthy is, none of the patients showed a significant modification of liver function.

CONCLUSIONS: Our study demonstrates that G-CSF administration and BMSC collection from the peripheral blood is possible and safe in patients with liver cirrhosis. The optimal dose to mobilize BMSC in cirrhotics is 15 microg/kg/day. At this dose, G-CSF does not seem to modify the residual liver function in cirrhotic patients.

DOI10.1111/j.1365-2036.2008.03670.x
Alternate JournalAliment. Pharmacol. Ther.
PubMed ID18315586